Charles River Laboratories International (NYSE:CRL) EVP Sells $65,488.00 in Stock

Charles River Laboratories International, Inc. (NYSE:CRL) EVP Joseph Laplume sold 400 shares of the stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $163.72, for a total transaction of $65,488.00. Following the sale, the executive vice president owned 23,716 shares of the company’s stock, valued at approximately $3,882,783.52. This represents a 1.66% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Charles River Laboratories International Trading Down 1.3%

NYSE CRL opened at $223.74 on Friday. The firm’s fifty day moving average is $195.91 and its two-hundred day moving average is $175.83. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $228.88. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.10 and a current ratio of 1.37. The firm has a market cap of $11.01 billion, a PE ratio of -143.43, a P/E/G ratio of 6.78 and a beta of 1.61.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, November 5th. The medical research company reported $2.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.32 by $0.11. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $990.43 million. Charles River Laboratories International had a positive return on equity of 15.78% and a negative net margin of 2.07%.The business’s revenue was down .5% on a year-over-year basis. During the same quarter last year, the company posted $2.59 earnings per share. Analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Hedge Funds Weigh In On Charles River Laboratories International

Hedge funds have recently bought and sold shares of the company. Tema Etfs LLC purchased a new stake in Charles River Laboratories International during the fourth quarter worth $26,000. Cromwell Holdings LLC raised its stake in shares of Charles River Laboratories International by 542.9% during the 2nd quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company’s stock worth $27,000 after buying an additional 152 shares during the last quarter. Neo Ivy Capital Management purchased a new stake in shares of Charles River Laboratories International in the 2nd quarter worth about $29,000. Rothschild Investment LLC grew its stake in Charles River Laboratories International by 82.4% in the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 84 shares during the last quarter. Finally, Atlantic Union Bankshares Corp purchased a new position in Charles River Laboratories International during the 3rd quarter valued at about $31,000. 98.91% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

CRL has been the subject of several recent research reports. Robert W. Baird set a $224.00 price target on Charles River Laboratories International in a report on Friday, January 9th. Barclays upped their price objective on shares of Charles River Laboratories International from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Evercore ISI lifted their target price on shares of Charles River Laboratories International from $250.00 to $260.00 and gave the company an “outperform” rating in a report on Tuesday, January 13th. TD Cowen reiterated a “buy” rating on shares of Charles River Laboratories International in a research note on Thursday. Finally, Mizuho set a $215.00 price objective on shares of Charles River Laboratories International in a research report on Friday, January 9th. Ten investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Charles River Laboratories International has a consensus rating of “Moderate Buy” and a consensus target price of $209.46.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.